Author:
Suzman D L,Zhou X C,Zahurak M L,Lin J,Antonarakis E S
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Urology,Oncology
Reference26 articles.
1. Paller CJ, Antonarakis ES . Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions. Clin Adv Hematol Oncol 2013; 11: 14.
2. Boccon‐Gibod L, Djavan B, Hammerer P, Hoeltl W, Kattan M, Prayer‐Galetti T et al. Management of prostate‐specific antigen relapse in prostate cancer: a European consensus. Int J Clin Pract 2004; 58: 382–390.
3. Moul JW, Wu H, Sun L, McLeod DG, Amling C, Donahue T et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 2004; 171: 1141–1147.
4. Smith MR, Manola J, Kaufman DS, George D, Oh WK, Mueller E et al. Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate‐specific antigen level after radical prostatectomy and/or radiation therapy. Cancer 2004; 101: 1569–1574.
5. Rosenbaum E, Zahurak M, Sinibaldi V, Carducci MA, Pili R, Laufer M et al. Marimastat in the treatment of patients with biochemically relapsed prostate cancer: a prospective randomized, double-blind, phase I/II trial. Clin Cancer Res 2005; 11: 4437–4443.